Skip to main content
[Preprint]. 2024 Jun 4:2024.06.03.597178. [Version 1] doi: 10.1101/2024.06.03.597178

Figure 1: Hallmarks of tumor-experienced T cells are absent in NDMM.

Figure 1:

1A: Experimental diagram and clinical time course. ADT=antibody-derived tag; GEX=gene expression; TCR=T cell receptor.

1B: TotalVI-UMAP of CD8+ T cells colored by cluster.

1C: Mean expression of proteins (top) or genes (bottom) by cluster.

1D: TotalVI-UMAP of CD8+ T cells colored by gene set score.

1E: Mean gene set score by cluster.

1F: PRETX frequency of exhausted-like/exhausted T cells quantified by single-cell sequencing, including public data,58 and separated by tumor type; p calculated by Wilcoxon rank sum test. AML=acute myeloid leukemia; CRC=colorectal cancer; LC=lung cancer; EC=esophageal cancer; BCL=B cell lymphoma.

1G: PRETX frequency of PD-1++CD39+ T cells quantified by mass cytometry, including public data,9 and separated by tumor type; p calculated by Wilcoxon rank sum test.

1H: Frequency of exhausted-like (left) or activated (right) cells in NDMM patients at PRETX and healthy controls, by tissue; p calculated by Wilcoxon rank sum test.

1I: Frequency of BM (left panel) or PB (right panel) exhausted-like or activated cells (x-axis) and BM tumor cells quantified by clinical immunohistochemistry (y-axis) at PRETX; r and p calculated by Spearman method.

1J: PRETX frequency of pMHC-tet+CD8+ T cells by peptide family and tissue; lines grouped by patient.